[SCHEDULE 13G] Bitwise MARA Option Income Strategy ETF SEC Filing

Rhea-AI Filing Summary

Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund report beneficial ownership of 2,536,881 shares of Enliven Therapeutics common stock, representing 5.17% of the class based on 49,069,258 shares outstanding as reported by the issuer on May 14, 2025. The filing is a Schedule 13G and shows the reporting persons hold sole voting and sole dispositive power over the reported shares with no shared voting or dispositive power.

The filing includes a joint filing statement (Exhibit I) and a certification that the securities were not acquired to change or influence control of the issuer, indicating passive disclosure under the Schedule 13G rules.

Insights

Financial Analyst

TL;DR: Polar Capital reports a passive 5.17% stake (2,536,881 shares) in Enliven Therapeutics with sole voting/dispositive power.

From an investor lens, a disclosed >5% stake is material because it meets statutory reporting thresholds and signals substantial ownership by a sophisticated institutional group. The schedule identifies sole voting and dispositive power for 2,536,881 shares and cites 49,069,258 shares outstanding as the basis for the 5.17% figure. The Schedule 13G format and the certification in Item 10 indicate this is reported as passive ownership rather than an active effort to change control.

Corporate Governance Expert

TL;DR: The joint Schedule 13G filing documents passive ownership by Polar Capital entities and includes a joint filing exhibit.

The filing names three reporting persons and includes a Joint Filing Statement (Exhibit I) confirming coordinated filing responsibility while preserving individual accuracy responsibilities. Item 4 shows no shared voting or dispositive powers, and Item 10 contains a certification that the holdings were not acquired to influence control. These items collectively characterize the disclosure as passive and procedural under Rule 13d-1 rather than a governance-change declaration.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ENLIVEN THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

29337E102

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 29337E102

1

Names of Reporting Persons

Polar Capital Holdings Plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,536,881.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,536,881.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,536,881.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.17 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 29337E102

1

Names of Reporting Persons

Polar Capital LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,536,881.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,536,881.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,536,881.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.17 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 29337E102

1

Names of Reporting Persons

Polar Capital Funds PLC - Biotechnology Fund

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,536,881.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,536,881.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,536,881.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.17 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENLIVEN THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 6200 Lookout Road, Boulder, CO 80301
Item 2.
(a)	Name of person filing: Polar Capital Holdings Plc Polar Capital LLP Polar Capital Funds PLC - Biotechnology Fund
(b)	Address or principal business office or, if none, residence: 16 Palace Street London, SW1E 5JD George's Court, 54-62 Townsend Street Dublin 2, Ireland
(c)	Citizenship: United Kingdom
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 29337E102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,536,881
(b)	Percent of class: 5.17%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,536,881
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,536,881
	(iv) Shared power to dispose or to direct the disposition of: 0 Based on 49,069,258 shares outstanding as reported in the Issuer's Form 10-Q on May 14, 2025.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Information for each Subsidiary is incorporated on the respective cover pages.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Polar Capital Holdings Plc

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	08/14/2025

Polar Capital LLP

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	08/14/2025

Polar Capital Funds PLC - Biotechnology Fund

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	08/14/2025

Exhibit Information

Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Polar Capital Holdings PLC By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital LLP By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital Funds PLC - Biotechnology Fund By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer

FAQ

How many Enliven Therapeutics shares does Polar Capital beneficially own?

2,536,881 shares beneficially owned, as reported in this Schedule 13G.

What percentage of Enliven Therapeutics does that represent?

5.17% of the outstanding common stock, based on 49,069,258 shares outstanding as reported by the issuer on May 14, 2025.

Does Polar Capital have voting control over these shares?

Yes: the filing reports sole voting power for 2,536,881 shares and no shared voting power.

What type of filing was submitted and what does it indicate?

A Schedule 13G was filed; Item 10 contains a certification that the securities were not acquired to influence control, indicating a passive disclosure under Rule 13d-1.

Which entities filed this Schedule 13G?

Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund are the reporting persons named in the filing.